Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Merger or Acquisition (October 2011)
13 slides from Getinge Ab Class B's merger presentation, Oct 3, 2011
Slide 1: Acquisition of Atrium Medical
Acquisition of Atrium Medical 3 October, 2011
Slide 2: Strategic Rationale
Strategic Rationale • In line with Getinge’s stated intention of increasing its exposure to therapeutic devices and technologies in the cardiovascular space • Atrium’s product portfolio and call points are well aligned with Getinge’s existing business • Atrium provides a strong platform and innovati
Slide 3: Atrium Medical Today
Atrium Medical Today • Revenues: >$200 million estimated in 2011 • Employees: ~700 • Location Overview: • Headquarters / Research & Development / Manufacturing: Hudson, NH • Direct Sales Force: US, the UK, France, Germany, The Netherlands, Belgium, Australia, New Zealand and India • 116 distributors
Slide 4: Atrium Breakdown of Revenues
Atrium Breakdown of Revenues 2011E By Geography Rest of World 13% Europe 17% North America 70% 4 Getinge Group 20111003
Slide 5: Atrium Breakdown of Revenues (cont'd)
Atrium Breakdown of Revenues (cont’d) 2011E By Business OEM & Other Thrombus Management 3% 4% Biosurgery Cardiothoracic Drainage 15% 29% Vascular Grafts 8% Covered Stents 41% 5 Getinge Group 20111003
Slide 6: Covered Stents (Balloon Expandable)
Covered Stents (Balloon Expandable) • Global #2 position • Worldwide covered stents market size: >$350mm 6 Getinge Group 20111003
Slide 7: Cardiothoracic Drainage
Cardiothoracic Drainage • Global #1 position • US drainage market size: ~$50mm Ocean Oasis eDrain (Coming Soon) Express 7 Getinge Group 20111003
Slide 8: Biosurgery
Biosurgery • Fast-growing emerging player • US #4 position (in units) • US soft tissue market size: ~$300mm 8 Getinge Group 20111003
Slide 9: Thrombus Management
Thrombus Management [TBU] [TBU] Local Drug Delivery Thrombus Extraction 9 Getinge Group 20111003
Slide 10: Vascular Grafts
Vascular Grafts Advanta VS Vascular Graft Advanta VXT Vascular Graft Advanta SST Vascular Graft Flixene Trumpet Vascular Flixene IFG Vascular Graft Graft 10 Getinge Group 20111003
Slide 11: Atrium Has Grown Rapidly Over Recent Years
Atrium Has Grown Rapidly Over Recent Years ($ in millions) $250 $200+ $200 $170 $145 $150 $123 $102 $100 $94 $84 $67 $50 $0 2004A 2005A 2006A 2007A 2008A 2009A 2010A 2011E 11 Getinge Group 20111003
Slide 12: Transaction Overview
Transaction Overview • Getinge has signed a binding agreement to acquire Atrium Medical at an enterprise value of $680 million • 2012 EV / EBIT Multiple of 12.8x • Financing through existing credit facilities and a committed bridge loan of $300 million • Expected to close in Q4 2011 • Transaction is
Slide 13: Synergies & Financial Impact
Synergies & Financial Impact • Synergies are principally revenue driven • Atrium will receive access to Getinge’s extensive commercial network • Top-line growth is expected to be strong in coming years due to: • Revenue synergies • Sales force expansion • Dynamic new product pipeline • Transaction t